

CURRICULUM VITAE
December 2010

I. PERSONAL DATA

Name: Lynn Kennard Pershing
Birthdate: May17, 1953
Birthplace: Aberdeen, South Dakota
Citizenship: U.S.A.
Ethnicity W

II. EDUCATION

1975, B.S., Medical Technology, University of Wyoming, Laramie, Wyoming
1983, Ph.D., Biochemical Pharmacology and Toxicology, University of Utah, Salt
Lake City, Utah

III. PROFESSIONAL EXPERIENCE

A. Full-time Positions

1975 - 1977 Medical Technologist MT (ASCP) Clinical Chemistry and
Toxicology Tucson Medical Center, Tucson, Arizona
1977 - 1978 Medical Technologists MT (ASCP) Clinical Toxicology, Holy
Cross Hospital, Salt Lake City, Utah
1985 - 1987 Research Instructor, Division of Dermatology, Department of
Internal Medicine, University of Utah School of Medicine, Salt
Lake City, UT
1987 - 1992 Research Assistant Professor, Division of Dermatology, as
above.
1992 -1996 Research Associate Professor, Division of Dermatology, as
above.
1996 - 2001 Research Associate Professor, Department of Dermatology,
University of Utah School of Medicine, Salt Lake City, UT
2001- 2006 Research Professor, Department of Dermatology, University of
Utah School of Medicine, Salt Lake City, UT.
2006-present Independent Consultant

B. Editorial Experience

Archives of Dermatology, reviewer
Journal of Pharmaceutical Science, reviewer
Journal of Investigative Dermatology, reviewer
Pharmaceutical Research, reviewer
International Journal of Pharmaceutics, reviewer
European Journal of Pharmaceutical Sciences, reviewer
NIH ACTS reviewer
Prostaglandins, Leukotrienes & Essential Fatty Acids

C. Industrial Consultant

1. Aesgen, Inc. Princeton, NJ.
2. Agis Industries, LTD. / Clay Park Labs, Inc., Bronx, NY.
3. Alpharma USPD, Baltimore, MD.

4. Altana, Inc., Melville, NY.
5. Atrix Laboratories, Ft. Collins, CO
6. Baker Norton Pharmaceuticals, Miami, FL.
7. Biomedical Development Corporation, San Antonio, TX
8. Connectics, Palo Alto, CA.
9. Dermigen, Ft. Worth, TX.
10. Dermik Laboratories, Inc., College Station, PA.
11. DPT Laboratories, Ltd., San Antonio, TX.
12. EGO Pharmaceutics Pty, Limited, Australia
13. FDA, CDER and Generic Drugs, Washington, DC, USA
14. GeoCenters, Wright Patterson AF Base, Ohio
15. Glaxo Wellcome, Research Triangle Park, NC.
16. Helix BioPharma, Toronto, Canada
17. Hoffmann La Roche, Inc., Basel, Switzerland
18. 3M Corporation, St. Paul, MN.
19. Ortho Pharmaceutical, Raritan, NJ.
20. Perrigo, Bronx, NY
21. Pharmakinetics, Baltimore, MD.
22. Ranbaxy Pharmaceuticals, Princeton, NJ.
23. Raptim Research, Mumbai, India
24. Research Resources Development Inc., Lake Wylie, SC
25. Smith-Kline Beecham, NK
26. Stiefel Research Industries, Oakhill, NY.
27. TARO Pharmaceuticals USA, Inc., Hawthorne, NY.

IV. BIBLIOGRAPHY

A. PEER-REVIEWED PUBLICATIONS

1. Pershing, L.K., and Johanson, C.E. Acidosis-induced enhanced activity of the Na-K exchange pump in the in vivo choroid plexus: An ontogenetic analysis of possible role of cerebrospinal fluid pH homeostasis. *J Neurochem* 38:322-332, 1982.
2. Smith, Q.R., Pershing, L.K., and Johanson, C.E. A comparative analysis of extracellular fluid volume of several tissues as determined by six different markers. *Life Sciences* 29:449-456, 1981.
3. Russo, J. Jr., Russo, M.E., Smith, R.A., and Pershing, L.K. Assessment of quinidine gluconate for nonlinear kinetics following chronic dosing. *J Clin Pharmacol* 22:264-270, 1982.
4. Pershing, L.K., Peat, M.A., and Finkle, B.S. A high performance liquid chromatographic method for the quantitation of quinidine and its metabolites in plasma: An application to a quinidine-phenytoin drug interaction study. *J Anal Tox* 6:153-156, 1982.
5. Pershing, L.K., and Franklin, M.R. Cytochrome P-450 metabolic-intermediate complex formation and induction by macrolide antibiotics: A new class of agents. *Xenobiotica* 12:687-699, 1982.
6. Krueger, G.G., Wojciechowski, Z.J., Burton, S.A., Gilhar, A., Huether SE, Leonard LG, Rohr UD, Petelenz TJ, Higuchi WI, Pershing LK: The development of a rat/human skin flap served by a defined and accessible vasculature on a congenitally athymic (nude) rat. *Fundamental & Applied Toxicology* 5:S112-S121, 1985.
7. Wojciechowski, Z.J., Pershing, L.K., Huether, S.E., Leonard L.G., Burton, D.A.,

- Higuchi, W.I., Krueger, G. G. An experimental skin sandwich flap on an independent vascular supply for the study of percutaneous absorption. *J Invest Dermatol* 88:439-446, 1987.
8. Pershing, L.K., Huether, S., Conklin, R.L., Krueger, G. Cutaneous blood flow and percutaneous absorption: A quantitative analysis using a laser Doppler velocimeter and blood flow computer. *J Invest Dermatol* 92:355-359, 1989.
 9. Fenjyes, E.S., Gordon, D.A., Pershing, L.K., Williams, D.L., Taichman, L.B. Systemic distribution of apolipoprotein A secreted by grafts of epidermal keratinocytes: Implications for epidermal function and gene therapy. *Proc Natl Acad Sci USA* 86: 8803-8807, 1989.
 10. Pershing, L.K., Lambert, L.D., Knutson, K. Mechanism of ethanol-enhanced estradiol permeation across human skin in vivo. *Pharmaceut Res* 7(2):172-177, 1990.
 11. Parry, G.E., Bunge A.L., Silcox, G.D., Pershing, L.K., Pershing, D.W. Percutaneous absorption of benzoic acid across human skin. I. In vitro experimentation and mathematical modeling. *Pharmaceut Res* 7(4): 230-236, 1990.
 12. Silcox, G.D., Parry, G.E., Bunge, A.L., Pershing, L.K., Pershing, D.W. Percutaneous absorption of benzoic acid across human skin. II. Prediction of an in vivo skin flap system using in vitro parameters. *Pharmaceut Res* 7(4): 352-358, 1990.
 13. Poncelet, C.E., Pershing, L.K., Lambert, L.D., Corlett, J. Ketoconazole Delivery To Human Skin By Topical And Oral Administration In Vitro and In Vivo. *The University Of Utah's Journal of Undergraduate Res* 2: 11-16, 1991.
 14. Pershing, L.K., Silver, B.S., Krueger, G.G., Shah, V.P., and Skelly, J. P. Feasibility of Measuring the Bioavailability of Topical Betamethasone Dipropionate in Commercial Formulations Using Drug Content in Skin and a Skin Blanching Assay. *Pharmaceut Res* 9(1):45-51, 1992.
 15. Parry, G.E., Dunn P., Shah, V.P., Pershing, L.K. Acyclovir Bioavailability in Human skin. *J Invest Dermatol*, 98:856-863, 1992.
 16. Law, M.Y., Pershing, L.K., Roberts, L.K. Arecoline-induced Skin Inflammation: Irritant or Allergic Dermatitis? *Int'l J Pharmaceut.* 88:251-260,1992.
 17. Pershing, L.K., Lambert, L.D., Shah, V.P., Lam, S.Y. Variability and Correlation of Chromameter and Tapestripping Methods with the Visual Skin Blanching Assay in the Quantitative Assessment of Topical 0.05% Betamethasone dipropionate Bioavailability in Humans. *Int'l J Pharmaceut* 86:201-210, 1992.
 18. Pershing, L.K. New Approaches to Assess Topical Corticosteroid Bioequivalence: Pharmacokinetics evaluation. *Int'l J Dermatol* 31: 14-20, 1992.
 19. Knutson, K., Harrison, D.J., Pershing, L.K., Goates, C.Y. Transdermal absorption of Steroids. *J Controlled Release* 24:95-108, 1993.
 20. Pershing, L.K., Parry, G.E., Lambert, L.D. Disparity of in vitro and in vivo oleic-acid enhanced-estradiol percutaneous absorption across human skin . *Pharmaceut Res* 10:1745-1750, 1994.
 21. Pershing, L.K., Corlett, J.L., Jorgensen C. In vivo pharmacokinetics and pharmacodynamics of topical ketoconazole and miconazole in human stratum corneum. *Antimicrob Agents Chemo* 38:90-95, 1994.
 22. Pershing, L.K., Lambert, L.D., Wright, E.D., Shah, V.P., Williams, R.L. Topical 0.05% betamethasone dipropionate: Pharmacokinetics and Pharmacodynamic Dose-Response studies in humans. *Arch Dermatol*,130:740-747, 1994.
 23. Pershing, L.K., Corlett, J.L. Circadian activity of topical 0.05% betamethasone dipropionate in human skin in vivo. *J Invest Dermatol* 102: 734-739, 1994.

24. Pershing, L.K., Bakhtian S., Wright, E.D., Rallis, T. Use of a Noninvasive Reflectance Colorimeter and Evaporimeter to Quantify and Differentiate Involved and Uninvolved Psoriatic from Healthy skin. *Skin Research and Technology*,140-144, 1995.
25. Pershing, L.K. Assessment of Topical Corticosteroid-Induced Skin Blanching Response using the Visual MacKenzie-Stoughton and Colorimetric Methods. *Drug Inform. J.* 29 (3): 923-934, 1995.
26. Rallis T.M., Bakhtian, S., Pershing, L.K., Krueger, G.G. Effects of 0.1% Retinoic Acid on Bateman's Actinic Purpura. *Arch Dermatol* 131:493-495, 1995.
27. Shah VP, Flynn GL, Yacobi A, Maibach HI, Fleischer NM, Franz TJ, Kaplan SA, Kawamoto J, Lesko LJ, Marty JP, Pershing LK, Schaefer H, Sequeira JA, Shrivastava SP, Wilkin J, Williams RL. Bioequivalence of topical dermatological dosage forms-- methods of evaluation of bioequivalence. AAPS/FDA Workshop on 'Bioequivalence of Topical Dermatological Dosage Forms-- Methods of Evaluating Bioequivalence', September 4-6, 1996, Bethesda, MD. *Skin Pharmacol Appl Skin Physiol* 11: 117-124, 1998.
28. Shah VP, Flynn GL, Yacobi A, Maibach HI, Bon C, Fleischer NM, Franz TJ, Kaplan SA, Kawamoto J, Lesko, LJ, Marty JP, Pershing LK, Schaefer H, Sequeira AJ, Shrivastava SP, Wilkin J, Williams RL. Bioequivalence of topical dermatological dosage forms--methods of evaluation and bioequivalence. *Pharm Res* 15(2): 167-1712, 1998.
29. Pershing, L.K., Lambert, L.D., Poncelet, C.E., Meline, J.C., Shah, V.P. Dermatopharmacokinetic Dose Response of Six Different Topical Corticosteroid Creams Using A Skin-Stripping Method. *Pharmaceut. Res*, 2008, in review
30. Singh, G.J.P., Adams W.P., Lesko L.J., Shah V.P., Molzon J.A., Williams R.L., Pershing L.K. Development of In Vivo Bioequivalence Methodology for Dermatologic Corticosteroids Base on Pharmacodynamic Modeling. *Clin Pharmacol Therapeut* 66(4):346-357,1999.
31. Hata, TR, Scholz TA, Gellerman W, McClane R, Alexeeva M, Irmakov I, Khachik F, Pershing, L.K. Noninvasive Raman Spectroscopic Detection of Carotenoids In Human Skin. *J Invest. Dermatol*, 1115: 441-448, 2000.
32. Pershing, L.K. Dermatopharmacokinetics For Assessing Bioequivalence of Topically Applied Products In Human Skin. *Cosmetics & Toiletries* 115:43-51, 2000.
33. Pershing LK, Bakhtian S., Poncelet C.E., Corlett J.L., Shah V.P. Comparison of Skin Stripping, In Vitro Release And Skin Blanching Methods To Measure Dose Response And Similarity Of Triamcinolone Acetonide Creams Strengths By Two Manufactured Sources. *J Pharm Sci* 91:1312-1323, 2002.
34. Pershing, L.K., Corlett, J.L., Nelson, J.L. Comparison of Dermatopharmacokinetics Vs. Clinical Efficacy Methods For Bioequivalence Assessment of Miconazole Nitrate Vaginal Cream, 2%. *Pharmaceu Res* 19: 270-277, 2002.
35. Pershing, L.K., Nelson, J.L., Corlett, J.L., Schrivastava, S., Hare, D.B., Shah, V.P. Assessment of Dermatopharmacokinetic Approach In The Bioequivalence Determination of Three Tretinoin Gel Products. *J Am Acad Dermatol*, 48:740-751, 2003.
36. Pershing, L.K., Riley, C.A., Corlett, J.L., and Crouch, D.A. Effects Of Vehicle On The Uptake And Elimination Kinetics Of Capasicinoids In Human Skin In Vivo. *Toxicol Appl Pharmacol.* 200:73-81, 2004.

37. Pershing, L.K., Riley, C.A., Corlett, J.L., Crouch, D.J. Assessment of Pepper Spray Product Potency in Asian and Caucasian Forearm Skin Using TEWL, Skin Temperature and Reflectance Colorimetry. *J Appl Toxicol* 26: 88-97, 2006.
38. Pershing, L. K., Nelson, J. L., Corlett, J. L., Briggs, G. B., Still, K. R., Jederberg, W. W. Disposition and Pharmacokinetics of a Lubricant Contaminant, 2, 6, Di-tert-Butyl 4-Nitrophenol in Grafted Human Skin. *J. Appl Toxicol* 26: 402-9, 2006.
39. Florell SR, Meyer LJ, Boucher KM, Porter-Gill PA, Hart M, Erickson J, Cannon-Albright LA, Pershing LK, Harris RM, Samlowski WE, Xone JJ, Leachman SA. Longitudinal assessment of the nevus phenotype in a melanoma kindred. *J invest Dermatol* 123(3): 576-82, 2004
40. Pershing, L. K., Chen, Y., Tchachuk A., Rausch, H. L., Petelenz, K., Corlett, J. L., Hobbs, M. R. NonCoding and Coding Region Polymorphisms in Class I Alcohol Dehydrogenase Form *ADH* Haplotypes With Altered Protein Expression And Activity to Alcohols *In Vitro* and *In Vivo*. *J Investig Dermatol* 128: 1633-40, 2008.
41. Pershing, L.K., Tirmuala, V. P., Nelson, J. L., Corlett, J. L., Lin, A., Meyer, L. J., Leachman, S.A. Reflectance Spectrophotometer: The Dermatologists' Sphygmomanometer For Skin Phototyping. *J Investig Dermatol* 128: 616-27, 2008.
42. Bakhtian, S., Pershing, L.K., Poncelet, C.P., Rallis, T. Use Of Reflectance Colorimetry, Transepidermal Water Loss, Skin Drug Concentrations And Visual Methods To Measure Dermatologic Corticosteroid Efficacy In Psoriasis. *Br J Dermatol*, in preparation
43. Pershing, L.K., Chen Y., Hobbs, M.R. NR3C1 Haplotype Correlates with Glucocorticosteroid Receptor α/β Expression In Vitro and Skin Blanching Response In Vivo. *J Investig Dermatol*, in preparation.
44. Pershing, L.K., Petelenz, K., Corlett, J.L. Influence Of Vehicle On Emax Parameters And Relative Potency Assessment Of Topical Glucocorticosteroid Products. *Clin Pharmacol and Ther*, in preparation.
45. Pershing, L.K., Petelenz, K., Corlett, J.L. Race Effects on Emax Parameters Of Topical Glucocorticosteroid Products. *Clin Pharmacol and Ther*, in preparation.
46. Pershing, L.K., Wright, E.D., Lambert, L., Shah, V.P. Differential cutaneous uptake and clinical efficacy of oral versus topical ketoconazole in humans with Tinea pedis. *Pharmaceut Res.*, in preparation.
47. Pershing, L.K., Corlett, J.L., Nelson J.L. Establishment of Topical Glucocorticosteroid Potency In Human Skin Using Drug Uptake and Skin Blanching Response. *Pharmaceut Res*, in preparation.

B. BOOK CHAPTERS

1. Franklin, M. R., Pershing, L.K., and Bornheim, L.M. Characterization of rat hepatic cytochrome P-450 subpopulations by anion exchange chromatography and metabolic-intermediate complex formation. In: *Cytochrome P-450, Biochemistry, Biophysics, and Environmental Implications*. E Heitanen, M. Laitinen, and D. Hanninen (eds), Elsevier Biomedical Press, Amsterdam, pp. 307-310, 1982.
2. Pershing, L.K., Krueger, G.G. New animal models for bioavailability studies. In: *Pharmacology and the Skin*, B Shroot & H Schaefer (eds), S. Karger, Basel, pp. 57-69, 1987.
3. Pershing, L.K., Krueger, G.G. Human skin sandwich flap model for percutaneous absorption. In: *Percutaneous Absorption, Second Edition*, RL Bronaugh & HI

- Maibach (eds), Marcel Dekker, Inc., New York, pp. 397-414, 1989.
4. Krueger, G.G. and Pershing L.K. Skin Xenografts and Their Utility in Pharmacological Research. In: Pharmacology of the Skin. Mukhtar H., (ed.), CRC Press, Boca Raton, FL, 1992, pp 41-72.
 5. Pershing, L.K., Lambert, L.D., Shah, V.P., Lam, S.Y. Reproducibility and Correlation of the Minolta™ Chromameter, Tapestripping and Visual Skin Blanching in the Assessment of Bioavailability of Topical 0.05% Betamethasone Dipropionate Formulations. In: Prediction of Percutaneous Penetration, Vol II, RC Scott, RH Guy and J Hadgraft, eds., IBC Technical Services LTD., London, 1992.
 6. Krueger, G.G. and Pershing, L.K. Human Skin Xenografts to Athymic Rodents as a System to Study Toxins Delivered To Or Through Skin. In: Health Risk Assessment Through Dermal and Inhalation Exposure and Absorption of Toxicants. Wang, Knaak and Maibach, (eds), CRC Press, New York, 1992.
 7. Pershing, L.K., Parry, G.E., Bunge A., Krueger, G.G., Shah V.P. Assessment of Topical Corticosteroid Bioavailability In Vivo and In Vitro. In: Topical Drug Bioavailability, Bioequivalence and Penetration. VP Shah and HI Maibach (eds), Plenum Publishing Corp., New York, pp. 351-365,1993.
 8. Shah, V.P., and Pershing, L.K. The Stripping Technique to Assess Bioequivalence of Topically applied Formulations. In: Prediction of Percutaneous Penetration, Vol III, RC Scott, RH Guy and J Hadgraft, eds., IBC Technical Services, LTD., London, 1993.
 9. Knutson, K., and Pershing, L.K. Topical Drugs, in Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro, AR (ed), Mack Publishing Co., Easton, PA, 1995.
 10. Knutson, K. and Pershing, L.K. Topical Drugs, in Remington: The Science and Practice of Pharmacy, 20th Edition, Gennaro, AR (ed), Mack Publishing Co., Easton, PA, 2000.
 11. Pershing, L.K. Use of Dermatopharmacokinetics To Assess Bioequivalence and Bioavailability Of Topically Applied Products In Human Subjects, in press, 2000.
 12. Knutson, K. and Pershing, L.K. Topical Drugs, in Remington: The Science and Practice of Pharmacy, 20th Edition, Gennaro, AR (ed), Mack Publishing Co., Easton, PA, 2005.

C. ABSTRACTS

1. Pershing, L.K., and Johanson, C.E. Effect of acute metabolic acid-base distortions on choroid plexus Na and K in the developing postnatal rat. Fed Amer Soc Exp Biol, Abst. #778, April 1979.
2. Pershing, L.K., and Johanson, C.E. Redistribution of Na and K in rat CNS during respiratory acidosis and alkalosis. Soc Neurosci, Abst. #1017:308, Nov. 1979.
3. Pershing, L.K., and Franklin, M.R. Induction of rat hepatic cytochrome P-450 by macrolide antibiotics. Fed Amer Soc Exp Biol, Abst. #8534, 1982.
4. Russo, M.E., Russo, J., Smith, R.A., and Pershing, L.K. The effect of phenytoin on quinidine pharmacokinetics. Drug Intell Clin Pharm 6:480, 1982.
- *5. Pershing, L.K., and Krueger, G.G. Quantitative assessment of the disparity between in vivo and in vitro percutaneous absorption of caffeine. Acad Pharmaceut Sci 15(2):76, 1985.
6. Pershing, L.K., Wojciechowski, Z.J., Petelenz, T.J. and Krueger, G.G. Enhanced percutaneous absorption of benzoic acid across a nude/rat skin sandwich flap following phenylephrine induced vasoconstriction. Clin Res 34(1):163A, 1986.

7. Pershing, L.K., Conklin, R.L., Krueger, G.G. Effects of reduced body temperature on blood flow and percutaneous absorption of ¹⁴C benzoic acid across grafted nude rat skin. *Clin Res* 34(2):418A, 1986.
8. Pershing, L.K., Conklin, R.L., Krueger, G.G. An analysis of percutaneous absorption and binding of caffeine in vivo and in vitro. *Clin Res* 34(2):773A, 1986.
9. Pershing, L.K., Conklin, R.L., Manning, C.A., Krueger, G.G. Effects of oral cyclosporine therapy on percutaneous absorption, in vitro versus in vivo. *Pharmaceut. Res* 3(5):53S, 1986.
- *10. Pershing, L.K., Conklin, R.L., Manning, C.A., Petelenz, T.J., Pershing, D.W., Krueger, G.G. Enhanced percutaneous absorption across grafted rat skin following cyclosporine therapy. *Clin Exp Derm*, 11. 1987.
- *11. Pershing, L.K., Franklin, M.R., Ritter, J.K. Clotrimazole. Just another cytochrome P-450 inducer? *Pharmacologist* 28: 240, 1986.
12. Pershing, L.K., Lambert, L., Krueger, G.G. Influence of temporal blood flow variation on percutaneous absorption across the skin sandwich flap. *Pharmaceut Res* 4(2):S70, 1987.
- *13. Pershing, L.K., Conklin, R.L., Krueger, G.G. Assessment of the variation in percutaneous absorption across the skin sandwich flap. *Clin Res* 88(4):511, 1987.
- *14. Pershing, L.K., Lambert, L., Krueger, G.G. Correlation of cutaneous blood flow between a laser Doppler velocimeter and an electromagnetic blood flow meter using the skin sandwich flap. *Clin Res* 35:181A, 1987.
15. Pershing, D.W., Lighty, J.S., Parry, G.E., Pershing, L.K., Conklin, R.L., Krueger, G.G., Bunge, A.L. *Chemical Engineering Principles in the Analysis of Toxic Incineration and Transdermal Drug Delivery*. American Institute of Chemical Engineering, Minneapolis, MN, August 1987.
- *16. Pershing, L.K., Jederberg, W.J., Conklin, R.L., Krueger, G.G. Mechanisms of cyclosporine-enhanced percutaneous absorption in the skin sandwich flap model. *Clin Res* 36:684A, 1988.
17. Pershing, L.K., Silver, B.S., Krueger, G.G., Shah, V., Lam, C., Skelley, J. Parameters of defining the correlation of stratum corneum drug content with vasoconstriction using topical corticosteroids. *Clin Res* 37:235A, 1989.
- *18. Pershing, L.K., Lambert, L.D., Knutson, K. Partition coefficients and solubilities of estradiol in a variety of vehicles predict the in vivo flux across the human skin sandwich flap. *J Invest Dermatol* 92(3):499, 1989.
19. Silcox, G.D., Parry, G.E., Bunge, A.L., Pershing, D.W., Pershing, L.K. Prediction of benzoic acid absorption across the human skin sandwich flap with a mathematical model using in vitro physicochemical parameters. *Clin Res* 37:766A, 1989.
- *20. Pershing, L.K., Lambert, L.D., Krueger, G.G. Oral cyclosporine A increases the diffusivity of skin in vivo thereby enhancing percutaneous absorption. *Clin Res* 37:727A, 1989.
21. Goates, C.Y., Knutson, K., Pershing, L.K. A comparison of the barrier properties of human and hairless mouse stratum corneum. *Pharmaceut Res* 6(9):S-112, 1989.
- *22. Parry, G.E., Pershing, L.K. Disparity of estradiol permeability coefficients in human skin in vitro and in vivo with 5% oleic acid in ethanol. *Pharmaceut Res* 6(9):S-110, 1989.
23. Pershing, L.K., Lambert, L.D. In Vivo Cutaneous Pharmacokinetics of Topical Tretinoin in Human Skin. *Pharmaceut Res* 7(9): s-191, 1990.
22. Pershing, L.K., Corlett, J. Cremophor-induced increase in human skin permeability. *J*

- Invest. Dermatol. 94(4): 565, 1990.
- *25. Pershing, L.K., Lambert, L.D., Knutson, K. Ethylacetate-increased Progesterone and Estradiol Permeation across Human Skin In Vivo. *Pharmaceut. Res* 8: S-144, 1991.
 - *26. Pershing, L.K., Corlett, J., Shah, V.P. In Vivo Bioavailability of Topical Ketoconazole and Miconazole in Human Stratum Corneum. *Pharmaceut Res* 8: S-255, 1991.
 27. Pershing, L.K., Corlett, J., Jorgensen, C., Krueger, G.G., Shah, V.P., Lam, S. In Vivo Ketoconazole Bioavailability in Human Stratum Corneum Following Oral and Topical Administration. *Pharmaceut Res* 8:S-308, 1991.
 28. Pershing, L.K., Corlett, J., Poncelet, C., Jorgensen, C., Shah, VP, Lam, S. Comparison of Topical Antifungal Bioavailability using In Vivo and In Vitro Human Skin Models. *Pharmaceut Res* 8: S-205, 1991.
 - *29. Parry, G.E., Pershing, L.K., and Knutson, K. Influence of Ethanol on Tortuosity of Estradiol Permeation Across Human skin. *Pharmaceut Res* 8: S-146, 1991.
 - *30. Pershing, LK, Corlett, J. In vivo cutaneous kinetics of ketoconazole in human skin following oral and topical administration. *J Invest Dermatol*, 1991.
 31. Krueger, G.G., Jorgensen, C., Pershing, L.K. Chemical and Pharmacologic equivalence of trade and compounded Minoxidil. *Pharmaceut Res* 8: S-208, 1991.
 32. Pershing LK, Corlett J, Jorgensen C, Krueger GG, Shah VP, Wright ED. Disparity in ketoconazole activity in vitro versus tinea pedis subjects following oral and topical administration. *Clin Res* 40:535A, 1992.
 33. Wright ED, Lambert L, Krueger GG, Shah VP, Pershing LK, Differential cutaneous uptake and clinical efficacy of oral versus topical ketoconazole in humans with tinea pedis. *Clin Res* 40:464A, 1992.
 34. Pershing, L.K., Corlett, J., Wright E.D., Shah V.P., Williams, R.L. Assessment of a Topical Corticosteroid Dose Response in Humans by Three Methods. *Pharmaceut Res* 9:S171, 1992.
 35. Pershing, L.K., Lambert, L.D., Wright, E.D., Shah, V.P., Williams, R.L. Equilibration delay between pharmacokinetics and pharmacodynamics of 0.05% betamethasone dipropionate in human skin. *Pharmaceut Res* 9:S305,1992.
 36. Knutson, K., Harrison D., Goates, C.Y., Pershing, L.K. Transdermal Absorption of Steroids. *J Controlled Release* 1992.
 - *37. Pershing, L.K., Corlett, J., Jorgensen, C., Krueger, G.G., Shah V.P., Wright, E.D. Disparity in ketoconazole activity in vitro versus Tinea pedis subjects following oral and topical administration. *J Invest Dermatol.*, 98(4): 651, 1992.
 38. Wright, E.D., Lambert, L., G.G. Krueger, Shah, V.P., Pershing, L.K. Differential cutaneous uptake and clinical efficacy of oral versus topical ketoconazole in humans with Tinea pedis. *J Invest Dermatol.*, 98(4): 604, 1992.
 - *39. Pershing, L.K., Lambert, L.D. Mechanisms of vehicle-enhanced β -estradiol permeation across the human skin sandwich flap. *Pharmaceut Res* 10:S-255, 1993.
 40. Rallis TM, Bakhtian S, Pershing LK, Krueger GG. A double-blind paired comparison efficacy and safety study of a retinoic acid formulation and a vehicle control in patients with Bateman's senile or actinic purpura. *Clin Res* 41:424A, 1993.
 41. Knutson K, Pershing L, Oakeson R, Wright ED, Krueger GG. Clinical, TEWL, and in vivo spectroscopic assessment of psoriatic lesions during oral cyclosporine therapy. *Clin Res* 41:420A, 1993.
 42. Wright ED, Weidner M, Poncelet C, Pershing L, Krueger GG. Comparison of objective and subjective methods of assessing efficacy of treatment of psoriasis using once vs. twice daily cyclosporine. *Clin Res* 41:128A, 1993.

- *43. Pershing, L.K., Bakhtian, S., Wright, E.D., Rallis, T. Use of a noninvasive colorimeter and evaporimeter to quantify and differentiate involved and uninvolved psoriasis from healthy skin. *Skin Pharmacology*, 1994.
44. Law, M.Y., Pershing, L.K., Meline, J. Wound Healing Profiles in Nude Mice Skin: UVB vs UVB+C. *Pharmaceut. Res* 1994.
45. Pershing, L.K., Corlett, J.L., Meline, J., Poncelet, C.P. Chronopharmacology of topical corticosteroids. *J Controlled Rel*, in press, 1994.
46. Pershing, L.K., Lambert, L.D., Corlett, J.L., Poncelet, C.P., Meline, J. There are three not seven classes of topical corticosteroids. *J. Invest Dermatol* 102:, 1994.
- *47. Singh G.J.P., Lesko L.J., Shah, V.P., Adams W.P, Molzon J.A., Williams, R.L., Pershing, L.K. Pharmacodynamic modeling to develop bioequivalence methodology for dermatologic corticosteroids.
- *48. Pershing, L.K., Meline, J., Corlett, J., Wickham, A., Knutson, K. Topical drug uptake in tapestripped human skin as a function of wound healing in vivo. *J Invest Dermatol* 104:591,1995.
49. Law, M.Y.L., Poncelet, C.E., Meline, J.C., Pershing, L.K. Differential response to UV spectra between grafted and ungrafted mouse and human skin on nude mouse. *J Invest Dermatol* 104:655,1995.
- *50. Zone JJ, Taylor TB, Corlett J, Error B, Meyer LJ, Pershing LK. Human skin engrafted on athymic mice as an animal model for bullous pemphigoid. *J Invest Dermatol* 104:557,1995.
- *51. Pershing, L.K. Use of Grafted human skin on Athymic Mice and Rats to quantitate chemical absorption and elimination from skin in vivo. *AIHCE*, 1995.
- *52. Pershing, L.K., Meline, J., Corlett, J., Law, M.Y.L. Opposite in vivo dermatokinetics of topical testosterone, mannitol and LHRH in stripped vs. retinoic acid-treated human skin. *Pharmaceut Res* 12:S-248, 1995.
- *53. Singh, G.J.P., Picaquadio, D., Pershing, L.K., Willich, K, Lambert, L.D., Adams, W.P., Shuirmann, D., Shrivastaca, S., Shah, V.P., Lesko, L.J. Pharmacodynamic bioequivalence studies on betamethasone dipropionate cream. *Clin Pharmacol and Therapeutic*, in press, 1995.
- *54. Pershing, L.K., Meline, J., Wickham, A., Knutson, K. Drug uptake in tapestripped vs retinoid-treated human skin in vivo: Influence of lipid composition and biophysical status. *Pharmaceut. Res*, 1996.
55. Pershing, L.K., Corlett, J., Wickham, A., Knutson, K. Role of Stratum Corneum Lipids and Proteins in the Renormalization of Solute Uptake into Tapestripped Skin. *J Invest Dermatol* 1997.
56. Pershing, L.K., Corlett, J. Potency Assessment of Clobetasol Propionate in Four Commercial Formulations Using a Colorimeter and Population-Based Emax Modeling. *J Invest Dermatology*, 1998.
57. Pershing, L.K., Nelson, J.L, Corlett, J.L, Dilate, M., Sahara, A. Dermatopharmacokinetics of 1% clindamycin phosphate gel in human stratum corneum in vivo. *Pharmaceut Res* 1998.
58. Lehman P, Agarwal N, Pershing LK, Parsell D, Franz T. Viafoam: A unique, new delivery Vehicle for Topical Medications. *JAAD* 1998.
59. Pershing, L.K., Corlett, J.L., Nelson, J.L. Bioequivalence Assessment Of 2% Miconazole Nitrate Cream Using Dermatopharmacokinetics, In Vitro Bioassay And Clinical Efficacy. *Pharmaceut Res*, 1999.
60. Pershing, L.K., Petelenz, K., Corlett, J.L. Propylene Glycol Alters Dermatologic

- Corticosteroid Activity in Asian Vs. Caucasian Skin. *J. Invest Dermatol*, 1999.
61. Pershing, L.K., Corlett, J.L. Potency Ranking Of Dermatologic Corticosteroids Using Dose Response Emax Parameters. *Pharmaceut Res*, 1999.
 62. Pershing, L.K. Petelenz, K., Corlett, J.L. Altered Topical Corticosteroid Emax Parameters In Asian Vs. Caucasian Skin With Propylene Glycol. *Pharmaceut Res*, 1999.
 63. Pershing, L.K., Nelson, J.L., Corlett, J.L. Bioavailability Assessment Of Four Imidazole Antifungal Creams In Human Forearm Skin Using Skin Stripping. *Pharmaceut. Res* 2000.
 64. Pershing, L.K, Corlett, J.L., Nelson, J.L. Vehicle Influence On 0.05% betamethasone dipropionate Uptake and Activity in Human Skin In Vivo: DPK Predicts The Skin Blanching Response. *Pharmaceut. Res*. 2000.
 65. Pershing, L.K., Nelson, J.L., Corlett, J.L. Hare, D.B., Shrivastava, S.P. Application Of Dermatopharmacokinetic Approach In The Assessment Of Clinically Bioequivalent And Bio-Inequivalent Tretinoin Gel Products. *J Invest Dermatol* 117(2): 547, 2001.
 66. Rausch, H.L., Pershing, L.K., Hobbs, M.R. Altered Asian Skin Blanching Responses to Dermatologic Corticosteroids Containing Alcohols Associated With An Alcohol Dehydrogenase 2 Polymorphism. *J Invest Dermatol* 117(2): 520, 2001.
 67. Pershing, L.K., Nelson, J.L., Corlett, J.L. Hare, D.B., Schrivastava, S.P. Concordance of Dermato-pharmacokinetic And Clinical Trial Bioequivalence Assessment of Tretinoin Gel, 0.025% in Human Skin. *Pharmaceut Res* 2001.
 68. Pershing, L.K., Corlett, J.L., Nelson, J.L. Lot Number Variability In Ketoconazole Cream, 2% Dermato-pharmacokinetic Profiles In Human Skin In Vivo. *Pharmaceut Res*, 2001.
 69. Pershing, L.K., Reilly, C.A., Crouch, D.J. Uptake and Activity of Capsaicin and Nonivamide in Human Skin As A Function Of Vehicle. *Toxicol Sci* 66(1S): 161, 2002.
 70. Hobbs, M. R., Tkachuk, A., Rausch, H.L., Pershing, L.K. Skin Blanching Response to Betamethasone Dipropionate Products Containing Alcohols Are Associated with Alcohol Dehydrogenase 1B Alleles. *J Invest Dermatol* 118: 263, 2002.
 71. Pershing, L.K., Corlett, J.L., Nelson, J.L. Potency Assessment Of A Dermatologic Corticosteroid Using Stratum Corneum Drug Content and The Skin Blanching Response. *Pharmaceut Res*, 2002.
 72. Pershing, L.K., Reilly, C.A., Crouch, D.J. Vehicle Composition Influences on Pharmacologic Effects And Kinetics Of Capsaicin In Human Skin. *Toxicol Sci*, 2003.
 73. Pershing, L.K., Tkachuk, A., Corlett, J.L., Hobbs, M.R. Topical Corticosteroid Activity in Human Skin Is Associated With Single Nucleotide Polymorphisms in Three Genes Involved in Alcohol Metabolism. *J Invest Dermatol*, 121(2) 2003.
 - *74. Pershing, L.K., Chen Y. Polymorphisms in Alcohol Dehydrogenase Influence Topical Capsaicinoid Activity in Human Skin. *Toxicol Sci*, 2004.
 75. Pershing, L.K., Chen Y., Hobbs, M.R. Glucocorticosteroid Receptor α/β Expression In Cultured Lymphocytes Correlates With Skin Blanching Response In Humans. *Pharmaceut Res*, 2005.
 76. Pershing, L.K., Siegel, P, Siegel G. Increased Bioavailability Of Miconazole In Human Skin With A Novel Polymer Vehicle. *Acad Amer Dermatol* 54(3):AB104, 2006.

* oral presentations